论文部分内容阅读
目的 评价控释格列吡嗪治疗 2型糖尿病的作用。方法 将 39名 2型糖尿病病人随机分为控释格列吡嗪组与格列齐特组。两组药物皆两周调整一次剂量 ,总疗程 12周。结果 治疗结束后 ,两组 Hb Alc均显著下降 (P<0 .0 1) ;控释格列吡嗪组每一时相血糖值皆较治疗前明显下降 (P<0 .0 1) ,格列齐特组空腹血糖值较治疗前明显下降 (P<0 .0 1) ,午餐后两小时血糖值较治疗前无明显下降 (P>0 .0 5 ) ;其余时相血糖值较治疗前下降 (P<0 .0 5 ) ;控释格列吡嗪组空腹血清胰岛素较治疗前下降 ,而格列齐特组空腹血清胰岛素较治疗前有所增加 ,但二者无统计学意义 (P>0 .0 5 ) ;两组病人肝、肾功及血常规均无明显变化。结论 格列吡嗪控释片对 2型糖尿病有良好的治疗作用。
Objective To evaluate the effect of controlled release glipizide on type 2 diabetes. Methods Thirty-nine patients with type 2 diabetes were randomly divided into controlled release glipizide group and gliclazide group. Two groups of drugs are adjusted dose once every two weeks, the total course of 12 weeks. Results After treatment, Hb Alc in both groups decreased significantly (P <0.01). The blood glucose level in each phase of controlled release glipizide group was significantly lower than that before treatment (P <0.01) The fasting blood glucose of the zlotet group was significantly lower than that before treatment (P <0.01), and the blood glucose level two hours after lunch had no significant difference (P> 0.05) (P <0.05). The fasting serum insulin in controlled-release glipizide group was lower than that before treatment, while the fasting serum insulin in gliclazide group was higher than that before treatment, but there was no significant difference between the two groups (P> 0 .0 5); two groups of patients with liver, kidney function and blood no significant changes. Conclusion Glipizide controlled-release tablets have a good therapeutic effect on type 2 diabetes mellitus.